Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Linus D. Kloker"'
Autor:
Linus D. Kloker, Branko Calukovic, Katrin Benzler, Alexander Golf, Sebastian Böhm, Sven Günther, Marius Horger, Simone Haas, Susanne Berchtold, Julia Beil, Mary E. Carter, Tina Ganzenmueller, Stephan Singer, Abbas Agaimy, Robert Stöhr, Arndt Hartmann, Thomas Duell, Sandra Mairhofer, Fabian Fohrer, Niels Reinmuth, Lars Zender, Ulrich M. Lauer
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
NUT carcinoma (NC) is a rare and extremely aggressive form of cancer, usually presenting with intrathoracic or neck manifestations in adolescents and young adults. With no established standard therapy regimen and a median overall survival of only 6.5
Externí odkaz:
https://doaj.org/article/937409fb0e814f379cae06b3619b90ce
Autor:
Linus D. Kloker, Susanne Berchtold, Irina Smirnow, Julia Beil, Andreas Krieg, Bence Sipos, Ulrich M. Lauer
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-13 (2020)
Abstract Background Oncolytic virotherapy is an upcoming treatment option for many tumor entities. But so far, a first oncolytic virus only was approved for advanced stages of malignant melanomas. Neuroendocrine tumors (NETs) constitute a heterogenou
Externí odkaz:
https://doaj.org/article/7feb99fdfa9c48e58f33df3aadf9220f
Autor:
Jana Koch, Julia Beil, Susanne Berchtold, Dina Mönch, Annika Maaß, Irina Smirnow, Andrea Schenk, Mary E. Carter, Linus D. Kloker, Tobias Leibold, Philipp Renner, Marc-H. Dahlke, Ulrich M. Lauer
Publikováno v:
Viruses, Vol 15, Iss 2, p 363 (2023)
Oncolytic virotherapy constitutes a promising treatment option for many solid cancers, including peritoneal carcinomatosis (PC), which still represents a terminal stage of many types of tumors. To date, the in vitro efficacy of oncolytic viruses is m
Externí odkaz:
https://doaj.org/article/822e82baacc441038ab92e364129dec5
Autor:
Irina Smirnow, Linus D Kloker, Andreas Krieg, Julia Beil, Ulrich M. Lauer, Susanne Berchtold, Bence Sipos
Background: Oncolytic virotherapy is an upcoming treatment option for many tumor entities. But so far, a first oncolytic virus only was approved for advanced stages of malignant melanomas. Neuroendocrine tumors (NETs) constitute a heterogenous group
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4631cd502cb0253bfe4c66db2c6a145c
https://doi.org/10.21203/rs.2.20785/v2
https://doi.org/10.21203/rs.2.20785/v2
Autor:
Linus D Kloker, Susanne Berchtold, Irina Smirnow, Julia Beil, Andreas Krieg, Bence Sipos, Ulrich M Lauer
Background: Oncolytic virotherapy is an upcoming treatment option for many tumor entities. But so far, a first oncolytic virus only was approved for advanced stages of malignant melanomas. Neuroendocrine tumors (NETs) constitute a heterogenous group
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b60429e8b5f4b7b59d1c9024d0b416f
https://doi.org/10.21203/rs.2.20785/v1
https://doi.org/10.21203/rs.2.20785/v1
Autor:
Linus D Kloker, Susanne Berchtold, Irina Smirnow, Julia Beil, Andreas Krieg, Bence Sipos, Ulrich M Lauer
Publikováno v:
BMC Cancer
BMC Cancer, Vol 20, Iss 1, Pp 1-13 (2020)
BMC Cancer, Vol 20, Iss 1, Pp 1-13 (2020)
Background: Oncolytic virotherapy is an upcoming treatment option for many tumor entities. But so far, a first oncolytic virus only was approved for advanced stages of malignant melanomas. Neuroendocrine tumors (NETs) constitute a heterogenous group
Autor:
Martin Schaller, Birgit Fehrenbacher, Andreas Krieg, Ulrich M. Lauer, Irina Smirnow, Susanne Berchtold, Linus D Kloker, Bence Sipos
Publikováno v:
Neuroendocrinology. 109(4)
Metastatic neuroendocrine cancer still constitutes a palliative situation, lacking promising treatment options. Oncolytic virotherapy, a novel type of virus-based immunotherapy, lyses tumor cells using genetically engineered viruses thereby activatin
Publikováno v:
Oncolytic virotherapy. 7
Oncolytic virotherapy constitutes an upcoming alternative treatment option for a broad spectrum of cancer entities. However, despite great research efforts, there is still only a single US Food and Drug Administration/European Medicines Agency-approv